Cargando…

Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3–5

Cardiovascular disease (CVD) is the leading cause of death in patients with chronic kidney disease (CKD). Osteoprotegerin (OPG), known to regulate bone mass by inhibiting osteoclast differentiation and activation, might also play a role in vascular calcification. Increased circulating OPG levels in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marques, Gustavo Lenci, Hayashi, Shirley, Bjällmark, Anna, Larsson, Matilda, Riella, Miguel, Olandoski, Marcia, Lindholm, Bengt, Nascimento, Marcelo Mazza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844415/ https://www.ncbi.nlm.nih.gov/pubmed/33510348 http://dx.doi.org/10.1038/s41598-021-82072-z

Ejemplares similares

Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease
por: Nascimento, M.M., et al.
Publicado: (2014)

Osteoprotegerin as a Marker of Atherosclerosis in Diabetic Patients
por: Augoulea, Areti, et al.
Publicado: (2013)

Bone Turnover Markers and Osteoprotegerin in Uncomplicated Pregnancy
por: Styczynska, Hanna, et al.
Publicado: (2009)

Giant Right Atrium: An Extreme Structural Damage Case Due to Rheumatic Heart Disease
por: Voltarelli, Clara L, et al.
Publicado: (2023)

Cardiovascular risk assessment in osteoporotic patients using osteoprotegerin as a reliable predictive biochemical marker
por: Barbu, Carmen G., et al.
Publicado: (2017)

State diagrams of the heart – a new approach to describing cardiac mechanics
por: Larsson, Matilda, et al.
Publicado: (2009)

Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications
por: Bjerre, Mette
Publicado: (2013)

Osteopontin and osteoprotegerin in atherosclerotic plaque – are they significant markers of plaque vulnerability?
por: Strobescu-Ciobanu, Cristina, et al.
Publicado: (2020)

The Brazilian Society of Nephrology and the Covid-19 Pandemic
por: de Abreu, Andrea Pio, et al.
Publicado: (2020)

Visualization of multimodal polymer-shelled contrast agents using ultrasound contrast sequences: an experimental study in a tissue mimicking flow phantom
por: Larsson, Malin, et al.
Publicado: (2013)

Endocardial border delineation capability of a novel multimodal polymer-shelled contrast agent
por: Larsson, Malin K, et al.
Publicado: (2014)

Association of Serum Osteoprotegerin Level With Myocardial Injury and Cardiovascular Calcification in Chronic Kidney Disease Patients
por: Okasha, Kamal M., et al.
Publicado: (2022)

Therapeutic implications of osteoprotegerin
por: Fili, Sofia, et al.
Publicado: (2009)

The role of osteoprotegerin in arthritis
por: Schett, Georg, et al.
Publicado: (2003)

Osteoprotegerin in Cardiometabolic Disorders
por: Pérez de Ciriza, C., et al.
Publicado: (2015)

Serum Osteoprotegerin Is an Independent Marker of Metabolic Complications in Non-DialysisDependent Chronic Kidney Disease Patients
por: Rymarz, Aleksandra, et al.
Publicado: (2021)

Expression of osteoprotegerin and osteoprotegerin ligand in giant cell tumor of bone and its clinical significance
por: YU, XIUCHUN, et al.
Publicado: (2013)

In-vitro sonothrombolysis using thick-shelled polymer microbubbles - a comparison with thin-shelled microbubbles
por: Janjic, Jovana, et al.
Publicado: (2020)

Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes
por: Røysland, Ragnhild, et al.
Publicado: (2012)

Biology of RANK, RANKL, and osteoprotegerin
por: Boyce, Brendan F, et al.
Publicado: (2007)

Immune Activation, Immunosenescence, and Osteoprotegerin as Markers of Endothelial Dysfunction in Subclinical HIV-Associated Atherosclerosis
por: D'Abramo, Alessandra, et al.
Publicado: (2014)

Plasma Protein Profiling Reveal Osteoprotegerin as a Marker of Prognostic Impact for Colorectal Cancer
por: Birgisson, Helgi, et al.
Publicado: (2018)

The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox
por: Özkalaycı, Flora, et al.
Publicado: (2018)

Association between osteoprotegerin gene polymorphisms and cardiovascular disease in type 2 diabetic patients
por: Guo, Changlei, et al.
Publicado: (2013)

Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients
por: Lee, Jung Eun, et al.
Publicado: (2013)

Serum osteoprotegerin is associated with pulse pressure in kidney transplant recipients
por: Nemeth, Zsofia K., et al.
Publicado: (2015)

Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients
por: Bernardi, Stella, et al.
Publicado: (2017)

Circulating Osteoprotegerin in Chronic Kidney Disease and All-Cause Mortality
por: Kamińska, Joanna, et al.
Publicado: (2021)

Pure red cell aplasia and anti-erythropoietin antibodies in patients on hemodialysis: a report of two cases and a literature review
por: Lacreta, Gabriela, et al.
Publicado: (2018)

Serum levels of osteoprotegerin, RANK-L & vitamin D in different stages of osteoarthritis of the knee
por: Naik, Sanjukta, et al.
Publicado: (2021)

Osteoprotegerin induction in response to microbial infection
por: Takada, Yasunari, et al.
Publicado: (2012)

Expression and Regulation of Osteoprotegerin in Adipose Tissue
por: An, Juan-Ji, et al.
Publicado: (2007)

Osteoprotegerin and MTHFR gene variations in rheumatoid arthritis: association with disease susceptibility and markers of subclinical atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2022)

Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases
por: Dutka, Mieczysław, et al.
Publicado: (2021)

Plasma osteoprotegerin predicts adverse cardiovascular events in stable coronary artery disease: the PEACE trial
por: Ma, Teng, et al.
Publicado: (2023)

Increased Monocyte/Lymphocyte Ratio as Risk Marker for Cardiovascular Events and Infectious Disease Hospitalization in Dialysis Patients
por: Muto, Reiko, et al.
Publicado: (2022)

Closed-loop real-time simulation model of hemodynamics and oxygen transport in the cardiovascular system
por: Broomé, Michael, et al.
Publicado: (2013)

Cardiovascular and Renal Effects of Bromocriptine in Diabetic Patients with Stage 4 Chronic Kidney Disease
por: Mejía-Rodríguez, Oliva, et al.
Publicado: (2013)

IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand
por: Guerra-Menéndez, Lucia, et al.
Publicado: (2013)

RANK, RANKL and osteoprotegerin in bone biology and disease
por: Wright, H. L., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_67c9277cj1mghc6f6rbbb0vehr